Treatment of Hospital infections in the US account for about $10 billion in annual healthcare expenditures. Gram-positive infections, caused by organisms such as staphylococcus aureus, streptococcus pneumoniae, and enterococcus have an outer lipid cell membrane, and are a major cause of morbidity, mortality and cause complicated infections of many different tissues such as the skin, bloodstream, heart, lung, meninges, bone, and joints.
Nevakar has developed a proprietary and potentially safer and efficacious approach to overcome these life-threatening infections.
Our product is a novel formulation that has the potential to provide an improved pharmacokinetic profile, reduced nephrotoxicity and better antibiotic penetration to tissues that were previously difficult to treat.
|Product CandidatesTherapeutic Area||Research||Preclinical||Phase I||Phase II||Phase III|